Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)

A. Sobrero, H. J. Lenz, C. Eng, W. Scheithauer, G. Middleton, W. Chen, R. Esser, J. Nippgen, H. Burris

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii163
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this